Edition:
United States

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

14.29EUR
25 May 2018
Change (% chg)

€-0.55 (-3.71%)
Prev Close
€14.84
Open
€14.85
Day's High
€14.94
Day's Low
€14.13
Volume
610,535
Avg. Vol
305,455
52-wk High
€19.42
52-wk Low
€8.53

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.20
Market Cap(Mil.): €318.86
Shares Outstanding(Mil.): 22.31
Dividend: --
Yield (%): --

Financials

  MDG1k.DE Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -0.61 -- --
ROI: -14.03 -7.54 13.04
ROE: -17.04 -10.33 14.90

German stocks - Factors to watch on May 15

BERLIN/FRANKFURT, May 15 The following are some of the factors that may move German stocks on Tuesday:

May 15 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

May 14 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

Apr 11 2018

BRIEF-Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​

* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011

Mar 22 2018

BRIEF-Medigene Receives Approvals For First Clinical Trial With MDG1011

* SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011

Feb 21 2018

BRIEF-Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR

* MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 01 2018

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

Dec 11 2017

BRIEF-Medigene Sells US-Rights For Veregen, Raises 2017 Guidance

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017

Dec 05 2017

Earnings vs. Estimates